After 2 weeks of treatment, a significant improvement of clinical symptoms, blood gas analysis parameters (PaO 2/FiO 2 and PaCO 2), and pulmonary function parameters (forced expiratory volume [FEV] 1 and FEV1%) was observed in patients treated with Myrtol® standardized in comparison to the control group. Symptoms such as convulsive cough and pressure headache are relieved, and the nasal congestion is cleared.

The first study to date the secretolytic and secretomotoric effects of GeloMyrtol® forte was performed in vivo in healthy volunteers and published on 1995 from Behrbohm et al.

GeloMyrtol ® forte has a liberating and beneficial effect like inhalation from within: the active ingredients are absorbed by the body and pass through the bloodstream into the lungs and paranasal sinuses. Myrtol® standardized is also investigated as a long-term treatment in patients with chronic bronchitis during winter time. Furthermore, the experimentally proven inhibition of the enzyme 5-lipoxygenase in leukemic basophil and eosinophil leukocytes of rats and the production of prostaglandin E2 in mucous membranes of teat cisterns after topical administration of TPA (tetradecanoylphorbol-13-acetate) indicate a wide range of anti-inflammatory potential by blocking many different inflammatory pathways. Anti-inflammatory effects of Myrtol standardized and other essential oils on alveolar macrophages from patients with chronic obstructive pulmonary disease.

These properties allow the inhibition of oxidative stress, and the attenuation of subsequent damage induced by infections or environmental impacts. BauchschmerzenBemerken Sie eine Befindlichkeitsstörung oder Veränderung während der Behandlung, wenden Sie sich an Ihren Arzt oder Apotheker. In decades of therapeutic use in clinics and practices, it has proven to be very well tolerated and effective.

De Mey and Riechelmann conducted a multicenter, randomized, double-blind, placebo-controlled clinical trial where Myrtol® standardized (GeloMyrtol® forte) was tested against placebo in patients with chronic sinusitis for a time period of 3 months. For instance, in ARS, the incidence of bacterial infections is estimated to be only 2–10%, with a secondary bacterial infection occurring only in 0.